1 day Ago By ABMN Staff
Ultragenyx Pharmaceutical ( NASDAQ:RARE – Get Free Report ) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of ($1.58) per share and revenue of $145.
98 million for the quarter. Ultragenyx Pharmaceutical ( NASDAQ:RARE – Get Free Report ) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.
39) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.07).
The company had revenue of $164.88 million during the quarter, compared to the consensus estimate of $163.23 million.
Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%.
On average, analysts expect Ultragenyx Pharmaceutical to post $-5 EPS for the current fiscal year and $-3 EPS for the next fiscal year. Ultragenyx Pharmaceutical Price Performance NASDAQ RARE opened at $38.07 on Wednesday.
The firm has a market capitalization of $3.57 billion, a price-to-earnings ratio of -6.00 and a beta of 0.
61. The company’s fifty day moving average is $37.66 and its two-hundred day moving average is $43.
42. Ultragenyx Pharmaceutical has a 52-week low of $29.59 and a 52-week high of $60.
37. Analyst Ratings Changes Read Our Latest Stock Analysis on RARE Insider Activity In other Ultragenyx Pharmaceutical news, EVP Thomas Richard Kassberg sold 6,028 shares of the business’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $42.
10, for a total transaction of $253,778.80. Following the completion of the sale, the executive vice president now directly owns 265,238 shares of the company’s stock, valued at approximately $11,166,519.
80. The trade was a 2.22 % decrease in their position.
The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website . Also, EVP Karah Herdman Parschauer sold 2,990 shares of the firm’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $42.
88, for a total transaction of $128,211.20. Following the completion of the transaction, the executive vice president now directly owns 54,991 shares in the company, valued at $2,358,014.
08. This trade represents a 5.16 % decrease in their position.
The disclosure for this sale can be found here . Insiders have sold 124,643 shares of company stock valued at $5,256,268 over the last three months. 5.
50% of the stock is owned by insiders. About Ultragenyx Pharmaceutical ( Get Free Report ) Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Featured Stories Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter ..
